US6043057A
(en)
*
|
1988-09-16 |
2000-03-28 |
Vitec Aktiebolag |
Recombinant systems for expression of the cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
|
IT1253009B
(en)
*
|
1991-12-31 |
1995-07-10 |
Sclavo Ricerca S R L |
DETOXIFIED IMMUNOGENIC MUTANTS OF COLERIC TOXIN AND TOXIN LT, THEIR PREPARATION AND USE FOR THE PREPARATION OF VACCINES
|
GB9513371D0
(en)
|
1995-06-30 |
1995-09-06 |
Biocine Spa |
Immunogenic detoxified mutant toxins
|
GB9326174D0
(en)
|
1993-12-22 |
1994-02-23 |
Biocine Sclavo |
Mucosal adjuvant
|
US6436407B1
(en)
|
1994-08-26 |
2002-08-20 |
The Administrators Of The Tulane Educational Fund |
Mutant enterotoxin effective as a non-toxic adjuvant
|
US6019982A
(en)
*
|
1994-08-26 |
2000-02-01 |
The Administrators Of The Tulane Educational Fund |
Mutant enterotoxin effective as a non-toxic oral adjuvant
|
GB9603314D0
(en)
*
|
1996-02-16 |
1996-04-17 |
Biocine Spa |
Immunogenic detoxified mutant toxins
|
GB9622660D0
(en)
|
1996-10-31 |
1997-01-08 |
Biocine Spa |
Immunogenic detoxified mutant toxin
|
US6818222B1
(en)
|
1997-03-21 |
2004-11-16 |
Chiron Corporation |
Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
|
WO1999010372A1
(en)
|
1997-08-27 |
1999-03-04 |
Chiron Corporation |
Molecular mimetics of meningococcal b epitopes
|
AU3089599A
(en)
*
|
1998-03-18 |
1999-10-11 |
Smithkline Beecham Corporation |
Production of purified mutant enterotoxin for use as an adjuvant
|
US6033673A
(en)
*
|
1998-03-18 |
2000-03-07 |
The Administrators Of Tulane Educational Fund |
Double mutant enterotoxin for use as an adjuvant
|
NZ508366A
(en)
|
1998-05-01 |
2004-03-26 |
Chiron Corp |
Neisseria meningitidis antigens and compositions
|
US6576244B1
(en)
|
1998-06-19 |
2003-06-10 |
Acambis, Inc. |
LT and CT in parenteral immunization methods against helicobacter infection
|
DE69937571T2
(en)
*
|
1998-09-30 |
2008-09-04 |
The Government Of The United States Of America As Represented By The Uniformed Services University Of The Health Sciences |
MUTATEN CHOLERA HOLOTOXIN AS AID
|
EP1175144A4
(en)
*
|
1998-12-22 |
2002-10-30 |
Thompson Boyce Plant Res |
Orally immunogenic bacterial enterotoxins expressed in transgenic plants
|
WO2000039302A2
(en)
|
1998-12-31 |
2000-07-06 |
Chiron Corporation |
Improved expression of hiv polypeptides and production of virus-like particles
|
US7935805B1
(en)
|
1998-12-31 |
2011-05-03 |
Novartis Vaccines & Diagnostics, Inc |
Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
|
JP2002537355A
(en)
|
1999-02-26 |
2002-11-05 |
カイロン コーポレイション |
Use of bioadhesives and adjuvants for mucosal delivery of antigen
|
CA2689696C
(en)
|
1999-02-26 |
2013-08-06 |
Novartis Vaccines And Diagnostics, Inc. |
Microemulsions with adsorbed macromolecules and microparticles
|
US7115730B1
(en)
|
1999-04-27 |
2006-10-03 |
Chiron Srl |
Immunogenic detoxified mutant E. coli LT-A-toxin
|
US7384640B1
(en)
|
1999-09-30 |
2008-06-10 |
Wyeth Holdings Corporation |
Mutant cholera holotoxin as an adjuvant
|
WO2001070257A1
(en)
*
|
2000-03-17 |
2001-09-27 |
Uab Research Foundation |
Chimeric nontoxic mutants of enterotoxins as mucosal adjuvants for cell-mediated or humoral immunity
|
WO2001089456A2
(en)
|
2000-05-19 |
2001-11-29 |
The Administrators Of The Tulane Educational Fund |
Hybrid lt-a/ct-b holotoxin for use as an adjuvant
|
WO2002019968A2
(en)
*
|
2000-09-08 |
2002-03-14 |
University Of Maryland Biotechnology Institute |
Genetically engineered co-expression dna vaccines, construction methods and uses thereof
|
US20030162733A1
(en)
*
|
2000-11-27 |
2003-08-28 |
Haynes Joel R. |
Nucleic acid adjuvants
|
EP1363663B1
(en)
|
2001-01-12 |
2011-03-02 |
Novartis Vaccines and Diagnostics, Inc. |
Nucleic acid mucosal immunization
|
WO2002083855A2
(en)
|
2001-04-16 |
2002-10-24 |
Wyeth Holdings Corporation |
Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
|
AU2002346249B2
(en)
|
2001-06-07 |
2007-03-15 |
The Regents Of The University Of Colorado |
Mutant Forms of Cholera Holotoxin as an Adjuvant
|
IL159209A0
(en)
*
|
2001-06-07 |
2004-06-01 |
Wyeth Corp |
Mutant forms of cholera holotoxin as an adjuvant
|
US8481043B2
(en)
|
2001-06-22 |
2013-07-09 |
Cpex Pharmaceuticals, Inc. |
Nasal immunization
|
WO2003004657A1
(en)
|
2001-07-05 |
2003-01-16 |
Chiron Corporation |
Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof
|
EP2412242A3
(en)
|
2001-07-05 |
2012-06-13 |
Novartis Vaccines and Diagnostics, Inc. |
Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
|
AR045702A1
(en)
|
2001-10-03 |
2005-11-09 |
Chiron Corp |
COMPOSITIONS OF ASSISTANTS.
|
MX339524B
(en)
|
2001-10-11 |
2016-05-30 |
Wyeth Corp |
Novel immunogenic compositions for the prevention and treatment of meningococcal disease.
|
EP2572707A3
(en)
|
2002-02-20 |
2013-11-06 |
Novartis Vaccines and Diagnostics, Inc. |
Microparticles with adsorbed polypeptide-containing molecules
|
JP2005532789A
(en)
|
2002-03-15 |
2005-11-04 |
ワイス・ホールデイングス・コーポレーシヨン |
P4 protein variant of non-typeable Haemophilus influenzae with reduced enzymatic activity
|
US7785608B2
(en)
|
2002-08-30 |
2010-08-31 |
Wyeth Holdings Corporation |
Immunogenic compositions for the prevention and treatment of meningococcal disease
|
US20080159957A1
(en)
|
2002-10-01 |
2008-07-03 |
W Michael Kavanaugh |
Anti-Cancer and Anti-Infectious Disease Compositions and Methods for Using Same
|
WO2004060396A2
(en)
|
2002-12-27 |
2004-07-22 |
Chiron Corporation |
Immunogenic compositions containing phospholpid
|
US7731967B2
(en)
|
2003-04-30 |
2010-06-08 |
Novartis Vaccines And Diagnostics, Inc. |
Compositions for inducing immune responses
|
WO2005020964A1
(en)
|
2003-06-02 |
2005-03-10 |
Chiron Corporation |
Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
|
US8071652B2
(en)
|
2003-08-21 |
2011-12-06 |
The Board Of Regents Of The University Of Texas System |
Method of treating irritable bowel syndrome
|
GB0325494D0
(en)
*
|
2003-10-31 |
2003-12-03 |
Sbl Vaccin Ab |
Expression system
|
PL2336147T3
(en)
|
2003-12-17 |
2015-01-30 |
Janssen Alzheimer Immunotherap |
A beta immunogenic peptide carrier conjugates and methods of producing same
|
HUE026000T2
(en)
|
2003-12-17 |
2016-04-28 |
Wyeth Llc |
Immunogenic peptide carrier conjugates and methods of producing same
|
GB0410220D0
(en)
|
2004-05-07 |
2004-06-09 |
Kirkham Lea Ann |
Mutant pneumolysin proteins
|
CA2562037A1
(en)
|
2004-05-21 |
2005-12-08 |
Wyeth |
Altered fibronectin-binding protein of staphylococcus aureus
|
TW200613554A
(en)
|
2004-06-17 |
2006-05-01 |
Wyeth Corp |
Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
|
WO2007001423A2
(en)
|
2004-10-21 |
2007-01-04 |
Wyeth |
Immunogenic compositions of staphylococcus epidermidis polypeptide and polynucleotide antigens
|
US20100015211A1
(en)
|
2004-11-01 |
2010-01-21 |
Barnett Susan W |
Combination Approaches For Generating Immune Responses
|
US7709001B2
(en)
|
2005-04-08 |
2010-05-04 |
Wyeth Llc |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
KR20150061019A
(en)
|
2005-04-08 |
2015-06-03 |
와이어쓰 엘엘씨 |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
TW200806315A
(en)
|
2006-04-26 |
2008-02-01 |
Wyeth Corp |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
WO2008094188A2
(en)
|
2006-07-17 |
2008-08-07 |
Anza Therapeutics, Inc. |
Methods and compositions using listeria for enhancing immunogenicity by prime boost
|
AR064642A1
(en)
|
2006-12-22 |
2009-04-15 |
Wyeth Corp |
POLINUCLEOTIDE VECTOR THAT INCLUDES IT RECOMBINATING CELL THAT UNDERSTANDS THE VECTOR POLYPEPTIDE, ANTIBODY, COMPOSITION THAT UNDERSTANDS THE POLINUCLEOTIDE, VECTOR, RECOMBINATING CELL POLYPEPTIDE OR ANTIBODY, USE OF THE COMPOSITION AND A COMPOSITION AND A METHOD
|
EP2244695A1
(en)
|
2007-12-07 |
2010-11-03 |
Novartis AG |
Compositions for inducing immune responses
|
US9415006B2
(en)
|
2008-05-23 |
2016-08-16 |
The Regents Of The University Of Michigan |
Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same
|
EP2328928A2
(en)
|
2008-08-25 |
2011-06-08 |
Dana-Farber Cancer Institute, Inc. |
Conserved influenza hemagglutinin epitope and antibodies thereto
|
US20100092526A1
(en)
|
2008-09-26 |
2010-04-15 |
Nanobio Corporation |
Nanoemulsion therapeutic compositions and methods of using the same
|
EP2356135B1
(en)
|
2008-11-05 |
2017-10-25 |
Wyeth LLC |
Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (bhs) disease
|
EP2346529B1
(en)
|
2008-11-12 |
2016-02-10 |
Theraclone Sciences, Inc. |
Human m2e peptide immunogens
|
BRPI1005670A8
(en)
|
2009-01-05 |
2017-12-26 |
Epitogenesis Inc |
adjuvant compositions and processes of use.
|
EP2405758B1
(en)
|
2009-03-09 |
2016-04-27 |
Molecular Express, Inc. |
Methods and compositions for liposomal formulation of antigens and uses thereof
|
ITMI20090946A1
(en)
|
2009-05-28 |
2010-11-29 |
Novartis Ag |
EXPRESSION OF RECOMBINANT PROTEINS
|
ES2566646T3
(en)
|
2009-06-16 |
2016-04-14 |
The Regents Of The University Of Michigan |
Nanoemulsion vaccines
|
ES2613630T3
(en)
|
2010-05-23 |
2017-05-25 |
Aduro Biotech, Inc. |
Methods and compositions that use Listeria for an auxiliary cancer treatment
|
HUE048398T2
(en)
|
2010-06-04 |
2020-07-28 |
Wyeth Llc |
Vaccine formulations
|
US8658603B2
(en)
|
2010-06-16 |
2014-02-25 |
The Regents Of The University Of Michigan |
Compositions and methods for inducing an immune response
|
HUE052850T2
(en)
|
2010-08-23 |
2021-05-28 |
Wyeth Llc |
Stable formulations of neisseria meningitidis rlp2086 antigens
|
NZ607224A
(en)
|
2010-09-10 |
2014-11-28 |
Wyeth Llc |
Non-lipidated variants of neisseria meningitidis orf2086 antigens
|
SE535625C2
(en)
*
|
2010-10-28 |
2012-10-16 |
Toleranzia Ab |
New compositions and procedures for the treatment of autoimmune and allergic diseases
|
US20140287022A1
(en)
|
2011-04-26 |
2014-09-25 |
Molecular Express, Inc. |
Liposomal formulations
|
CN103717235A
(en)
|
2011-06-24 |
2014-04-09 |
埃皮托吉尼西斯有限公司 |
Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
|
ITMI20111182A1
(en)
|
2011-06-28 |
2012-12-29 |
Canio Buonavoglia |
VACCINE FOR CORONAVIRUS CANINO
|
MX2014005548A
(en)
|
2011-11-14 |
2014-08-21 |
Novartis Ag |
Immunogenic complexes of polyanionic carbomers and env polypeptides and methods of manufacture and use thereof.
|
SA115360586B1
(en)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
Neisseria meningitidis compositions and methods thereof
|
KR101763625B1
(en)
|
2012-03-09 |
2017-08-01 |
화이자 인코포레이티드 |
Neisseria meningitidis compositions and methods thereof
|
KR102057217B1
(en)
|
2012-06-20 |
2020-01-22 |
에스케이바이오사이언스 주식회사 |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
EP3608401A1
(en)
|
2012-07-05 |
2020-02-12 |
Ohio State Innovation Foundation |
Compositions and methods related to viral vaccines
|
MX2015000789A
(en)
|
2012-07-19 |
2015-05-07 |
Zoetis Llc |
Bovine influenza c virus compositions.
|
WO2014018724A1
(en)
|
2012-07-27 |
2014-01-30 |
Zoetis Llc |
Tick toxin compositions
|
MY167579A
(en)
|
2012-08-16 |
2018-09-20 |
Pfizer |
Glycoconjugation processes and compositions
|
DK2912186T3
(en)
|
2012-10-24 |
2021-02-22 |
Platelet Targeted Therapeutics Llc |
TREATMENT TARGETED TO BLOOD PLATES
|
KR20140075196A
(en)
|
2012-12-11 |
2014-06-19 |
에스케이케미칼주식회사 |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
KR20140075201A
(en)
|
2012-12-11 |
2014-06-19 |
에스케이케미칼주식회사 |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
ES2685894T3
(en)
|
2013-03-08 |
2018-10-15 |
Pfizer Inc. |
Immunogenic fusion polypeptides
|
JP2016512841A
(en)
|
2013-03-15 |
2016-05-09 |
ゾエティス・サービシーズ・エルエルシー |
B. Multivalent vaccine Interference effect of cattle on trehaloci infection
|
RU2662968C2
(en)
|
2013-09-08 |
2018-07-31 |
Пфайзер Инк. |
Immunogenic composition for neisseria meningitidis (options)
|
EP3063171B1
(en)
|
2013-11-01 |
2019-07-24 |
University Of Oslo |
Albumin variants and uses thereof
|
US9993541B2
(en)
|
2013-11-13 |
2018-06-12 |
University Of Oslo |
Outer membrane vesicles and uses thereof
|
WO2015071763A2
(en)
|
2013-11-15 |
2015-05-21 |
Oslo Universitetssykehus Hf |
Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
|
KR102049826B1
(en)
|
2014-01-21 |
2019-12-03 |
화이자 인코포레이티드 |
Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
|
EP4286000A3
(en)
|
2014-01-21 |
2024-02-14 |
Pfizer Inc. |
Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
|
EP3443983B1
(en)
|
2014-02-14 |
2022-07-20 |
Pfizer Inc. |
Immunogenic glycoprotein conjugates
|
US11083788B2
(en)
|
2014-10-10 |
2021-08-10 |
The Regents Of The University Of Michigan |
Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
|
EP3270959A1
(en)
|
2015-02-19 |
2018-01-24 |
Pfizer Inc |
Neisseria meningitidis compositions and methods thereof
|
WO2016141320A2
(en)
|
2015-03-05 |
2016-09-09 |
Northwestern University |
Non-neuroinvasive viruses and uses thereof
|
WO2016179034A2
(en)
|
2015-05-01 |
2016-11-10 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for stimulating immune response using potent immunostimulatory rna motifs
|
PT3334454T
(en)
|
2015-08-14 |
2022-12-20 |
Univ Melbourne |
Mycoplasma bovis compositions
|
CN108348593B
(en)
|
2015-08-31 |
2022-08-16 |
泰克诺瓦克斯股份有限公司 |
Human Respiratory Syncytial Virus (HRSV) virus-like particle (VLPS) based vaccines
|
CA3010977A1
(en)
|
2016-01-11 |
2017-07-20 |
Zoetis Services Llc |
Novel cross protective vaccine compositions for porcine epidemic diarrhea virus
|
WO2017158426A1
(en)
|
2016-03-14 |
2017-09-21 |
University Of Oslo |
Engineered immunoglobulins with altered fcrn binding
|
WO2017158421A1
(en)
|
2016-03-14 |
2017-09-21 |
University Of Oslo |
Anti-viral engineered immunoglobulins
|
WO2017201390A1
(en)
|
2016-05-19 |
2017-11-23 |
The Regents Of The University Of Michigan |
Novel adjuvant compositions
|
WO2017210215A1
(en)
|
2016-05-31 |
2017-12-07 |
The Government Of The United States Of America As Represented By The Secretary Of The Army |
Zika virus vaccine and methods of production
|
EP3471761A2
(en)
|
2016-06-21 |
2019-04-24 |
University Of Oslo |
Hla binding vaccine moieties and uses thereof
|
WO2017220753A1
(en)
|
2016-06-22 |
2017-12-28 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Pneumococcal polysaccharide-protein conjugate composition
|
EP3269385A1
(en)
|
2016-07-12 |
2018-01-17 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Pneumococcal polysaccharide-protein conjugate composition
|
WO2018096396A1
(en)
|
2016-11-22 |
2018-05-31 |
University Of Oslo |
Albumin variants and uses thereof
|
SG11201906519RA
(en)
|
2017-01-31 |
2019-08-27 |
Pfizer |
Neisseria meningitidis compositions and methods thereof
|
GB201703529D0
(en)
|
2017-03-06 |
2017-04-19 |
Cambridge Entpr Ltd |
Vaccine composition
|
WO2018183666A1
(en)
|
2017-03-31 |
2018-10-04 |
Boston Medical Center Corporation |
Methods and compositions using highly converved pneumococcal surface proteins
|
EP3641828B1
(en)
|
2017-06-23 |
2023-11-22 |
Affinivax, Inc. |
Immunogenic compositions
|
JP2020533338A
(en)
|
2017-09-07 |
2020-11-19 |
ユニバーシティ オブ オスロUniversity of Oslo |
Vaccine molecule
|
WO2019048936A1
(en)
|
2017-09-07 |
2019-03-14 |
University Of Oslo |
Vaccine molecules
|
EP3574915A1
(en)
|
2018-05-29 |
2019-12-04 |
Neovacs |
Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity
|
AU2020323498A1
(en)
|
2019-07-31 |
2022-03-03 |
Sk Bioscience Co., Ltd. |
Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
|
CA3164306A1
(en)
|
2020-01-10 |
2021-07-15 |
Lg Chem, Ltd. |
Composition comprising antigen-presenting cell co-expressing mhc and tumor antigen, and cancer treatment using same
|
AU2021211012A1
(en)
|
2020-01-24 |
2022-08-25 |
Aim Immunotech Inc. |
Methods, compositions, and vaccines for treating a virus infection
|
JP2023522050A
(en)
|
2020-04-16 |
2023-05-26 |
パーイミューン エスエーエス |
28KDA GST protein from Schistosoma for the treatment of vasculitis
|
EP3900739A1
(en)
|
2020-04-21 |
2021-10-27 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Synthetic streptococcus pneumoniae saccharide conjugates to conserved membrane protein
|
CA3192500A1
(en)
|
2020-09-17 |
2022-03-24 |
Laurent REBER |
Immunogenic product comprising an ige fragment for treating ige-mediated inflammatory disorders
|
EP4313132A1
(en)
|
2021-03-31 |
2024-02-07 |
Vib Vzw |
Vaccine compositions for trypanosomatids
|
WO2024069420A2
(en)
|
2022-09-29 |
2024-04-04 |
Pfizer Inc. |
Immunogenic compositions comprising an rsv f protein trimer
|